Both FOXA1 and FOXA2 factors act as pioneering chromatin remodelling factors for AR signalling and NE-specific transcription, with FOXA2 being strongly expressed in association with SYP-positive neuroendocrine prostate carcinoma samples, high-grade adenocarcinomas, and castration-resistant prostate cancer [151,152,170,171]. This evidence concerns the gene FOXA2 and prostate neuroendocrine neoplasm.